scholarly journals Liver transplantation for the solitary intrahepatic cholangiocarcinoma less than 2 cm in diameter

2017 ◽  
Vol 6 (5) ◽  
pp. 332-334
Author(s):  
Nobuhisa Akamatsu ◽  
Yoshihiro Sakamoto ◽  
Kiyoshi Hasegawa
HPB ◽  
2016 ◽  
Vol 18 ◽  
pp. e46-e47
Author(s):  
G. Sapisochin ◽  
M. Facciuto ◽  
N. Mehta ◽  
E. Vibert ◽  
R. Hernandez-Alejandro ◽  
...  

2018 ◽  
Vol 24 (5) ◽  
pp. 634-644 ◽  
Author(s):  
David D. Lee ◽  
Kristopher P. Croome ◽  
Kaitlyn R. Musto ◽  
Jose Melendez ◽  
Ghassan Tranesh ◽  
...  

2017 ◽  
Vol 22 ◽  
pp. 42-52 ◽  
Author(s):  
Dong-Hwan Jung ◽  
Shin Hwang ◽  
Gi-Won Song ◽  
Chul-Soo Ahn ◽  
Deok-Bog Moon ◽  
...  

2020 ◽  
Vol 11 (6) ◽  
pp. 1283-1290
Author(s):  
Ao Ren ◽  
Zhongqiu Li ◽  
Xuzhi Zhang ◽  
Ronghai Deng ◽  
Yi Ma

2021 ◽  
Vol 10 (18) ◽  
pp. 4073
Author(s):  
Oliver Beetz ◽  
Angelica Timrott ◽  
Clara A. Weigle ◽  
Andreas Schroeter ◽  
Sebastian Cammann ◽  
...  

Intrahepatic cholangiocarcinoma (ICC) is a rare disease with poor outcome, despite advances in surgical and non-surgical treatment. Recently, studies have reported a favorable long-term outcome of “very early” ICC (based on tumor size and absence of extrahepatic disease) after hepatic resection and liver transplantation, respectively. However, the prognostic value of tumor size and a reliable definition of early disease remain a matter of debate. Patients undergoing resection of histologically confirmed ICC between February 1996 and January 2021 at our institution were reviewed for postoperative morbidity, mortality, and long-term outcome after being retrospectively assigned to two groups: “very early” (single tumor ≤ 3 cm) and “advanced” ICC (size > 3 cm, multifocality or extrahepatic disease). A total of 297 patients were included, with a median follow-up of 22.8 (0.1–301.7) months. Twenty-one (7.1%) patients underwent resection of “very early” ICC. Despite the small tumor size, major hepatectomies (defined as resection of ≥3 segments) were performed in 14 (66.7%) cases. Histopathological analyses revealed lymph node metastases in 5 (23.8%) patients. Patients displayed excellent postoperative outcome compared to patients with “advanced” disease: intrahospital mortality was not observed, and patients displayed superior long-term survival, with a 5-year survival rate of 58.2% (versus 24.3%) and a median postoperative survival of 62.1 months (versus 25.3 months; p = 0.013). In conclusion, although the concept of a “very early” ICC based solely on tumor size is vague as it does not necessarily reflect an aggressive tumor biology, our proposed definition could serve as a basis for further studies evaluating the efficiency of either surgical resection or liver transplantation for this malignant disease.


2016 ◽  
Vol 25 (3) ◽  
pp. 401-404 ◽  
Author(s):  
Michel Rayar ◽  
Giovanni Battista Levi Sandri ◽  
Pauline Houssel-Debry ◽  
Christophe Camus ◽  
Laurent Sulpice ◽  
...  

Treatment of intrahepatic cholangiocarcinoma remains a major challenge. For an unresectable lesion without extrahepatic spread, liver transplantation could be a potential solution but it is still associated with poor oncologic results owing to the absence of effective neoadjuvant treatment. We report the case of a young man with locally advanced intrahepatic cholangiocarcinoma presenting with multiple intrahepatic metastases and vascular structure involvement. The lesion was significantly downstaged by a multimodal therapy including intra-arterial Yttrium-90 radioembolization, systemic chemotherapy and external radiotherapy, allowing liver transplantation. Three years after the procedure, oncologic outcome is excellent with no sign of recurrence.Multimodal therapy including Yttrium-90 radioembolization could be relevant as neoadjuvant treatment before liver transplantation for unresectable intrahepatic cholangiocarcinoma. Abbrevations: CA 19-9: carbohydrate antigen 19-9; FDG-PET: fluorodeoxyglucose positron emission tomography; HCC: hepatocellular carcinoma; ICC: intrahepatic cholangiocarcinoma; LT: liver transplantation; MRI: magnetic resonance imaging; PHC: perihilar cholangiocarcinoma; Ytt-90: Yttrium-90.


Sign in / Sign up

Export Citation Format

Share Document